2 results match your criteria: "Bristol-Myers Squibb Global Clinical Research[Affiliation]"
Discovery of New Immune Checkpoints: Family Grows Up.
Adv Exp Med Biol
April 2020
Bristol Myers Squibb Global Clinical Research, Shanghai, China.
Article Synopsis
- The first generation of immune checkpoint inhibitors (ICIs) including anti-CTLA-4 and anti-PD-1/anti-PD-L1 has shown remarkable success in cancer treatment, with nine drugs approved by Q1 2019.
- Despite their benefits, challenges remain such as limited response rates in late-stage patients, ineffective results in certain tumor types, and serious immune-related side effects.
- Clinicians have also noted cases where patients initially respond to treatment but later experience progression, prompting a search for next-generation immune checkpoint therapies.
Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype.
Alzheimers Dement
March 2013
Bristol-Myers Squibb Global Clinical Research, Wallingford, CT, USA.
Retrospective data are presented to support a spectrum of early Alzheimer's disease (AD) along a continuum defined by gender and genotype. The putative neurodegenerative mechanisms driving distinct phenotypes at each end of the spectrum are glial hypoactivity associated with early failure of synaptic cholinergic neurotransmission and glial overactivation associated with loss of neural network connectivity due to accelerated age-related breakdown of myelin. In early AD, male butyrylcholinesterase K-variant carriers with one or two apolipoprotein ɛ4 alleles have prominent medial temporal atrophy, synaptic failure, cognitive decline, and accumulation of aggregated beta-amyloid peptide.
View Article and Find Full Text PDF